The blockade of immune checkpoints in cancer immunotherapy

Cited by (1,122)

Items 401–500 of 1,122

1. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
   Charles G. Drake, Evan J. Lipson, Julie Renee Brahmer · 2013 · Nature Reviews Clinical Oncology
2. Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth
   Guanjun Deng, Zhihong Sun, Sanpeng Li, Xinghua Peng, Wenjun Li, Lihua Zhou, Yifan Ma, Ping Gong, Lintao Cai · 2018 · ACS Nano
3. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
   Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu · 2019 · Frontiers in Immunology
4. Targeting TGFβ signal transduction for cancer therapy
   Liu, Sijia, Ren, Jiang, ten Dijke, Peter · 2021 · Signal Transduction and Targeted Therapy
5. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
   Jeryl Jean Villadolid, Asim Amin · 2015 · PubMed Central
6. Supramolecular cancer nanotheranostics
   Zhou, Jiong, Rao, Lang, Yu, Guocan, Cook, Timothy R., Chen, Xiaoyuan, Huang, Feihe · 2021 · Chemical Society Reviews
7. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
   Rony Dahan, Emanuela I. Sega, John Engelhardt, Mark Selby, Alan J. Korman, Jeffrey V. Ravetch · 2015 · Cancer Cell
8. Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics
   Manu P. Kumar, Jinyan Du, Georgia Lagoudas, Jiao Yang, Andrew J. Sawyer, Daryl C. Drummond, Douglas A. Lauffenburger, Andreas Raue · 2018 · Cell Reports
9. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
   Abhishek Dinkarnath Garg, Lorenzo Galluzzi, Lionel Apétoh, Thaïs Baert, Raymond B. Birge, José Manuel Bravo‐San Pedro, Karine Breckpot, David Brough, Ricardo A. Chaurio, Mara Cirone et al. · 2015 · Frontiers in Immunology
10. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
    Alimuddin I. Zumla, Martin Rao, Robert S. Wallis, Stefan H. E. Kaufmann, Roxana Rustomjee, Peter Mwaba, Cristina Vilaplana, Dorothy Yeboah‐Manu, Jeremiah Muhwa Chakaya, Giuseppe Ippolito et al. · 2016 · The Lancet Infectious Diseases
11. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy
    Dangge Wang, Tingting Wang, Jianping Liu, Haijun Yu, Shi Jiao, Bing Feng, Fangyuan Zhou, Yuanlei Fu, Qi Yin, Pengcheng Zhang et al. · 2016 · Nano Letters
12. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence
    Nahlah Makki Almansour · 2022 · Frontiers in Molecular Biosciences
13. Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
    Serrels, Alan, Lund, Tom, Serrels, Bryan, Byron, Adam, McPherson, Rhoanne C., von Kriegsheim, Alexander, Gómez-Cuadrado, Laura, Canel, Marta, Muir, Morwenna, Ring, Jennifer E. et al. · 2015 · Cell
14. Cervical Cancer Immunotherapy: Facts and Hopes
    Louise Ferrall, Ken Yu Lin, Richard B. S. Roden, Chien‐Fu Hung, T.‐C. Wu · 2021 · Clinical Cancer Research
15. PD-1 Blockade Expands Intratumoral Memory T Cells
    Ribas, Antoni, Shin, Daniel Sanghoon, Zaretsky, Jesse, Frederiksen, Juliet, Cornish, Andrew, Avramis, Earl, Seja, Elizabeth, Kivork, Christine, Siebert, Janet, Kaplan-Lefko, Paula et al. · 2016 · Cancer Immunology Research
16. CAR-T cells: the long and winding road to solid tumors
    Maria Michela D’Aloia, Ilaria Grazia Zizzari, Benedetto Sacchetti, Luca Pierelli, Maurizio Alimandi · 2018 · Cell Death and Disease
17. Signal pathways of melanoma and targeted therapy
    Weinan Guo, Huina Wang, Chunying Li · 2021 · Signal Transduction and Targeted Therapy
18. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function
    Chun, Eunyoung, Lavoie, Sydney, Michaud, Monia, Gallini, Carey Ann, Kim, Jason, Soucy, Genevieve, Odze, Robert, Glickman, Jonathan N., Garrett, Wendy S. · 2015 · Cell Reports
19. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    Jiabei He, Ying Hu, Mingming Hu, Baolan Li · 2015 · Scientific Reports
20. Tailoring Materials for Modulation of Macrophage Fate
    Jinhua Li, Xinquan Jiang, Hongjun Li, Michael Gelinsky, Zhen Gu · 2021 · Advanced Materials
21. Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy
    Haonan Chang, Bei‐Yuan Liu, Yun‐Kun Qi, Yang Zhou, Yanping Chen, Kai‐Mai Pan, Wenwen Li, Xiuman Zhou, Weiwei Ma, Caiyun Fu et al. · 2015 · Angewandte Chemie International Edition
22. X-ray-activated nanosystems for theranostic applications
    Xiaofeng Chen, Jibin Song, Xiaoyuan Shawn Chen, Huanghao Yang · 2019 · Chemical Society Reviews
23. Organoid Models of Tumor Immunology
    Kanako Yuki, Ning Cheng, Michitaka Nakano, Calvin Jay Kuo · 2020 · Trends in Immunology
24. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Michael B. Bernstein, Sunil Krishnan, James W. Hodge, Joe Yujiao Chang · 2016 · Nature Reviews Clinical Oncology
25. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
    Hao Zhang, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu, Chengzeng Wang · 2023 · Molecular Cancer
26. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
    Kevin C. Soares, Agnieszka A. Rucki, Annie A. Wu, Kelly L. Olino, Qian Xiao, Yi Chai, Anthony Wamwea, Elaine O. Bigelow, Eric R. Lutz, Linda L. Liu et al. · 2014 · Journal of Immunotherapy
27. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
    Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou et al. · 2014 · Oncotarget
28. Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Theodore Scott Nowicki, Siwen Hu‐Lieskovan, Antoni Ribas · 2018 · The Cancer Journal
29. Immune checkpoint therapy in liver cancer
    Feng Xu, Tianqiang Jin, Yuwen Zhu, Chaoliu Dai · 2018 · Journal of Experimental & Clinical Cancer Research
30. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
    Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. Van Beijnum B, Patrycja M. Nowak-Sliwinska, Arjan W. Griffioen · 2021 · Nature Reviews Clinical Oncology
31. PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials
    Jason Madore, Ricardo E. Vilain, Alexander Maxwell Menzies, Hojabr Kakavand, James S. Wilmott, Jessica Hyman, Jennifer Holmes Yearley, Richard F. Kefford, John F. Thompson, Georgina Venetia Long et al. · 2014 · Pigment Cell & Melanoma Research
32. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
    Weilei Hu, Guosheng Wang, Dongsheng Huang, Meihua Sui, Yibing Xu · 2019 · Frontiers in Immunology
33. Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
    Dongre, Anushka, Rashidian, Mohammad, Reinhardt, Ferenc, Bagnato, Aaron, Keckesova, Zuzana, Ploegh, Hidde L., Weinberg, Robert A. · 2017 · Cancer Research
34. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
    Mayoux, Maud, Roller, Andreas, Pulko, Vesna, Sammicheli, Stefano, Chen, Stanford, Sum, Eva, Jost, Christian, Fransen, Marieke F., Buser, Regula B., Kowanetz, Marcin et al. · 2020 · Science Translational Medicine
35. Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity
    Aleksandra M. Dudek, Shaun Martin, Abhishek Dinkarnath Garg, Patrizia Agostinis · 2013 · Frontiers in Immunology
36. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
    Curtis A. Clark, Harshita B. Gupta, Gangadhara R. Sareddy, Srilakshmi Pandeswara, Shunhua Lao, Bin Yuan, Justin Michael Drerup, Alvaro Souto Padron, Jose Ramon Conejo-Garcia, Kruthi Murthy et al. · 2016 · Cancer Research
37. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
    Tingting Wang, Dangge Wang, Haijun Yu, Bing Feng, Fangyuan Zhou, Hanwu Zhang, Lei Zhou, Shi Jiao, Yaping Li · 2018 · Nature Communications
38. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis
    Nathan Edward Reticker-Flynn, Weiruo Zhang, Julia A. Belk, Pamela Antonia Basto, Nichole K. Escalante, Genay O.W. Pilarowski, Alborz Bejnood, Maria M. Martins, Justin A. Kenkel, Ian L. Linde et al. · 2022 · Cell
39. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
    Jonathan Trujillo, Randy F. Sweis, Riyue Bao, Jason J. Luke · 2018 · Cancer Immunology Research
40. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)
    Theresa L. Whiteside · 2013 · Biochemical Society Transactions
41. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets
    Quanyin Hu, Hongjun Li, Edikan A. Ogunnaike, Qian Chen, Huitong Ruan, Sarah Ahn, Elena Dukhovlinova, Yang Kang, Di Wen, Gianpietro Dotti et al. · 2021 · Nature Biomedical Engineering
42. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
    Chen, Degao, Zhang, Xiaomei, Li, Zhongjun, Zhu, Bo · 2021 · Theranostics
43. IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L
    Ilona Kryczek, Yanwei Lin, Nisha Nagarsheth, Dongjun Peng, Lili Zhao, Ende Zhao, Linda Vatan, Wojciech Szeliga, Yali Dou, Scott R. Owens et al. · 2014 · Immunity
44. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
    Ruea‐Yea Huang, Ariel Francois, AJ Robert McGray, Anthony J. Miliotto, Kunle O. Odunsi · 2016 · OncoImmunology
45. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
    Krzysztof M. Żak, P. Grudnik, Katarzyna Magiera‐Mularz, Alexander S. S. Dömling, Grzegorz Dubin, Tad A. Holak · 2017 · Structure
46. Alterations of immune response of non-small cell lung cancer with Azacytidine
    John M. Wrangle, Wei Wang, Alexander Koch, Hariharan Easwaran, Helai P. Mohammad, Xiaoyu Pan, Frank P. Vendetti, Wim Van Criekinge, Timothy DeMeyer, Zhengzong Du et al. · 2013 · Oncotarget
47. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
    Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han · 2018 · Journal of Hematology & Oncology
48. Tumor microenvironment and cancer therapy resistance
    Yu Sun · 2015 · Cancer Letters
49. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
    Karthik S. Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Karen Danoff · 2018 · CHEST Journal
50. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
    Aurélien Marabelle, Holbrook E K Kohrt, Idit Sagiv-Barfi, Bahareh Ajami, Robert C. Axtell, Gang Zhou, Ranjani Rajapaksa, Michael R. Green, James Anthony Torchia, Joshua Brody et al. · 2013 · Journal of Clinical Investigation
51. Myeloid‐derived suppressor cell heterogeneity in human cancers
    Samantha Solito, Ilaria Marigo, Laura Pinton, Vera Damuzzo, Susanna Mandruzzato, Vincenzo Bronte · 2014 · Annals of the New York Academy of Sciences
52. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
    Zhao, Yangjing, Shao, Qixiang, Peng, Guangyong · 2020 · Cellular & Molecular Immunology
53. Prospects of immune checkpoint modulators in the treatment of glioblastoma
    Matthias Preusser, Michael K. Lim, David A. Hafler, David A. Reardon, John Howard Sampson · 2015 · Nature Reviews Neurology
54. Bridging Bio–Nano Science and Cancer Nanomedicine
    Mattias Björnmalm, Kristofer J. Thurecht, Michael Michael, Andrew Mark Scott, Frank Caruso · 2017 · ACS Nano
55. CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
    Hye‐Jung Kim, Harvey Cantor · 2014 · Cancer Immunology Research
56. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
    Junyu Long, Anqiang Wang, Yi Bai, Jianzhen Lin, Xu Yang, Dongxu Wang, Xiaobo Yang, Yan Jiang, Haitao Zhao · 2019 · EBioMedicine
57. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9
    Richard Beatson, Virginia Tajadura‐Ortega, Daniela Achkova, Gianfranco Picco, Theodora-Dorita Tsourouktsoglou, Sandra Klausing, M. C. J. Hillier, John F. Maher, Thomas Noll, Paul R. Crocker et al. · 2016 · Nature Immunology
58. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis
    Lang Rao, Lei Wu, Zhida Liu, Rui Tian, Guocan Yu, Zijian Zhou, Kuikun Yang, Hong‐Gang Xiong, Anli Zhang, Guang-Tao Yu et al. · 2020 · Nature Communications
59. Mechanisms of drug resistance in HCC
    Alexandra D. Ladd, Sérgio M. Duarte, İlyas Şahin, Ali Zarrinpar · 2023 · Hepatology
60. PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
    Evan J. Lipson, Jeremy G. Vincent, Myriam Loyo, Luciane Tsukamoto Kagohara, Brandon S. Luber, Hao Wang, Haiying Xu, Suresh K. Nayar, Timothy S. Wang, David Sidransky et al. · 2013 · Cancer Immunology Research
61. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
    Robert Louis Ferris, Robert I. Haddad, Caroline Even, Makoto Tahara, Mikhail Vladimirovich Dvorkin, Tudor–Eliade Ciuleanu, Paul M. Clément, Ricard Mesı́a, Светлана Игоревна Кутукова, Lyubov Zholudeva et al. · 2020 · Annals of Oncology
62. At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    Andrew M. Intlekofer, Craig B. Thompson · 2013 · Journal of Leukocyte Biology
63. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
    Sara Gandini, Daniela Massi, Mario Mandalà · 2016 · Critical Reviews in Oncology/Hematology
64. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
    Stanley J. Oiseth, Mohamed S. Aziz · 2017 · Journal of Cancer Metastasis and Treatment
65. Immunotherapy in Lung Cancer: Current Landscape and Future Directions
    Hirva Mansurali Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, Greg Andrew Durm, Shadia Ibrahim Jalal · 2022 · Frontiers in Immunology
66. EGFR signaling pathway as therapeutic target in human cancers
    Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel Geoffrey Tenen · 2022 · Seminars in Cancer Biology
67. Cell Death in the Origin and Treatment of Cancer
    Andreas Strasser, David Lawrence Vaux · 2020 · Molecular Cell
68. Mechanisms regulating T-cell infiltration and activity in solid tumors
    Lanitis, E., Dangaj, D., Irving, M., Coukos, G. · 2017 · Annals of Oncology
69. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
    Ramaswamy Govindan, Aleksandra Szczęsna, Myung‐Ju Ahn, Claus-Peter Schneider, Pablo González Mella, Fabrice Barlési, Baohui Han, Doina Elena Ganea, Joachim von Pawel, Vladimir Ivanovich Vladimirov et al. · 2017 · Journal of Clinical Oncology
70. Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment
    Xianwen Ren, Lei Zhang, Yuanyuan Zhang, Ziyi Li, Nathan O. Siemers, Zemin Zhang · 2021 · Annual Review of Immunology
71. Spatial predictors of immunotherapy response in triple-negative breast cancer
    Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, Daniel Egle, Maurizio Callari, Begoña Bermejo, Matteo Dugo, Claudio Zamagni, Marc Thill, Anton Anton et al. · 2023 · Nature
72. The first five years of single-cell cancer genomics and beyond
    Nicholas E. Navin · 2015 · Genome Research
73. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
    Yuan Liu, Yufeng Cheng, Yong Xu, Zhifeng Wang, Xianhong Du, Chunyang Li, Jiali Peng, Lifen Gao, Xiaohong Liang, Chunhong Ma · 2017 · Oncogene
74. Durable antitumor responses to CD47 blockade require adaptive immune stimulation
    Sockolosky, Jonathan T., Dougan, Michael, Ingram, Jessica R., Ho, Chia Chi M., Kauke, Monique J., Almo, Steven C., Ploegh, Hidde L., Garcia, K. Christopher · 2016 · Proceedings of the National Academy of Sciences
75. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
    Hodi, F. Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris et al. · 2018 · Journal of Clinical Oncology
76. Lung Cancer Staging and Prognosis
    Gavitt Alida Woodard, Kirk D. Jones, David M. Jablons · 2016 · Cancer treatment and research
77. Defining the biological basis of radiomic phenotypes in lung cancer
    Grossmann, Patrick, Stringfield, Olya, El-Hachem, Nehme, Bui, Marilyn M, Rios Velazquez, Emmanuel, Parmar, Chintan, Leijenaar, Ralph TH, Haibe-Kains, Benjamin, Lambin, Philippe, Gillies, Robert J et al. · 2017 · eLife
78. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis
    Eunee Koh, Eun Jung Lee, Gi‐Hoon Nam, Yeonsun Hong, Eunji Cho, Yoosoo Yang, In‐San Kim · 2017 · Biomaterials
79. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
    Janet Lau, Jeanne Cheung, Armando Navarro, Steve Lianoglou, Benjamin Haley, Klára Tótpál, Laura Sanders, Hartmut Koeppen, Patrick Caplazi, Jacqueline McBride et al. · 2017 · Nature Communications
80. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
    Condamine, Thomas, Kumar, Vinit, Ramachandran, Indu R., Youn, Je-In, Celis, Esteban, Finnberg, Niklas, El-Deiry, Wafik S., Winograd, Rafael, Vonderheide, Robert H., English, Nickolas R. et al. · 2014 · Journal of Clinical Investigation
81. Epigenetic Therapeutics: A New Weapon in the War Against Cancer
    Nita Ahuja, Anup R. Sharma, Stephen B. Baylin · 2016 · Annual Review of Medicine
82. Phase I/Ib Clinical Trial of Sabatolimab, an Anti‐TIM‐3 Antibody, Alone and in Combination with Spartalizumab, an Anti‐PD‐1 Antibody, in Advanced Solid Tumors
    Curigliano, Giuseppe, Gelderblom, Hans, Mach, Nicolas, Doi, Toshihiko, Tai, David, Forde, Patrick M., Sarantopoulos, John, Bedard, Philippe L., Lin, Chia-Chi, Hodi, F. Stephen et al. · 2021 · Clinical Cancer Research
83. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
    Aaron Richard Hansen, Christophe Massard, Patrick Alexander Ott, Naomi Balzer Haas, Juanita Suzanne Lopez, Samuel Ejadi, John M. Wallmark, Bhumsuk Keam, Jean‐Pierre Delord, Rahul Raj Aggarwal et al. · 2018 · Annals of Oncology
84. Hyperprogressive disease: recognizing a novel pattern to improve patient management
    Stéphane Champiat, Roberto Ferrara, Christophe Massard, Benjamin Besse, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté · 2018 · Nature Reviews Clinical Oncology
85. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
    Wei, Spencer C., Anang, Nana-Ama A. S., Sharma, Roshan, Andrews, Miles C., Reuben, Alexandre, Levine, Jacob H., Cogdill, Alexandria P., Mancuso, James J., Wargo, Jennifer A., Pe’er, Dana et al. · 2019 · Proceedings of the National Academy of Sciences
86. Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy
    Yinchu Ma, Yuxue Zhang, Xiaoqiu Li, Yangyang Zhao, Min Li, Wei Jiang, Xinfeng Tang, Jiaxiang Dou, Ligong Lu, Feng Wang et al. · 2019 · ACS Nano
87. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
    Maddalena Centanni, Dirk Jan A. R. Moes, Iñaki F. Trocóniz, Joseph Ciccolini, J. G. Coen van Hasselt · 2019 · Clinical Pharmacokinetics
88. Implications of the tumor immune microenvironment for staging and therapeutics
    Janis Marie Taube, Jérôme Galon, Lynette Marie Sholl, Scott J. Rodig, Tricia R. Cottrell, Nicolás A. Giraldo, Alexander Spyridon Baras, Sanjay S. Patel, Robert A. Anders, David L. Rimm et al. · 2017 · Modern Pathology
89. Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
    Mana Taki, Kaoru Abiko, Masayo Ukita, Ryusuke Murakami, Koji Yamanoi, Ken D Yamaguchi, Junzo Hamanishi, Tsukasa Baba, Noriomi Matsumura, Masaki Mandai · 2021 · Clinical Cancer Research
90. The integration of inflammaging in age-related diseases
    Tamàs Fülöp, Jacek Maciej Witkowski, Fabiola Olivieri, Anis Larbi · 2018 · Seminars in Immunology
91. The promise and challenges of immune agonist antibody development in cancer
    Patrick A. Mayes, Kenneth W. Hance, Axel Hoos · 2018 · Nature Reviews Drug Discovery
92. Breast cancer heterogeneity and its implication in personalized precision therapy
    Liantao Guo, Deguang Kong, Jianhua Liu, Ling Zhan, Lan Luo, Weijie Zheng, Qingyuan Zheng, Chuang Chen, Shengrong Sun · 2023 · Experimental Hematology and Oncology
93. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response
    Feifei Hu, Chunjie Liu, Lanlan Liu, Qiong Zhang, An‐Yuan Guo · 2020 · Briefings in Bioinformatics
94. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
    Rui Kuai, Wenmin Yuan, Sejin Son, Jutaek Nam, Yao Xu, Yuchen Fan, Anna A. Schwendeman, James Jaehyun Moon · 2018 · Science Advances
95. Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy
    Chee Wee Ng, Jing Li, Kanyi Pu · 2018 · Advanced Functional Materials
96. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
    Mélodie Tazdait, Laura Mezquita, Jihene Lahmar, Roberto Ferrara, François Bidault, Samy Ammari, Corinne Balleyguier, David Planchard, Anas Gazzah, Jean‐Charles Soria et al. · 2017 · European Journal of Cancer
97. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
    Maute, Roy L., Gordon, Sydney R., Mayer, Aaron T., McCracken, Melissa N., Natarajan, Arutselvan, Ring, Nan Guo, Kimura, Richard, Tsai, Jonathan M., Manglik, Aashish, Kruse, Andrew C. et al. · 2015 · Proceedings of the National Academy of Sciences
98. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
    Anand Rotte, Jiangtao Jin, Vincent Lemaire · 2017 · Annals of Oncology
99. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
    Genevieve P. Hartley, Lyndah Chow, Dylan T. Ammons, William H. Wheat, STEVEN W. DOW · 2018 · Cancer Immunology Research
100. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
     Syreeta DeCordova, Abhishek Shastri, Anthony George Tsolaki, Hadida Yasmin, Lukas Klein, Shiv K. Singh, Uday Kishore · 2020 · Frontiers in Immunology